Sign inJoin waitlistJoin the waitlist

RO

Roisin O'Cearbhaill

Research Director, Gynecologic Medical Oncology Service · New York Presbyterian Hospital

Credentials: · ·

History

Gynecologic Medical Oncology Service · New York Presbyterian Hospital
Present
Solid Tumor · New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2005–2007
Mater Misericordiae University Hospital
2002–2005
National University of Ireland
1998–2002

Research

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2019 · 1,824 citations
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Cancer Discovery · 2021 · 515 citations

CA
Carol Aghajanian
59 papers
Dennis Chi
42 papers
YS
Yukio Sonoda
39 papers
RG
Rachel Grisham
36 papers
WT
William Tew
36 papers
Oliver Zivanovic
33 papers
NA
Nadeem Abu-Rustum
30 papers
KL
Kara Long
28 papers
GG
Ginger Gardner
27 papers
Dmitriy Zamarin
25 papers
JK
Jason Konner
22 papers
VM
Vicky Makker
21 papers

Clinical trials

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2020–2026
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal investigator · Active not recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2017–2027
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2016–2023
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2015–2026